serine has been researched along with Tauopathies in 18 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study investigated the expression of abnormal serine phosphorylation of insulin receptor substrate 1 (IRS1) in 157 human brain autopsy cases that included AD, tauopathies, α-synucleinopathies, TDP-43 proteinopathies, and normal aging." | 7.80 | Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. ( Arnold, SE; Arvanitakis, Z; Han, LY; Kazi, H; Kim, SF; Lee, EB; Lee, VM; Louneva, N; Toledo, JB; Trojanowski, JQ; Yarchoan, M, 2014) |
| " This study investigated the expression of abnormal serine phosphorylation of insulin receptor substrate 1 (IRS1) in 157 human brain autopsy cases that included AD, tauopathies, α-synucleinopathies, TDP-43 proteinopathies, and normal aging." | 3.80 | Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. ( Arnold, SE; Arvanitakis, Z; Han, LY; Kazi, H; Kim, SF; Lee, EB; Lee, VM; Louneva, N; Toledo, JB; Trojanowski, JQ; Yarchoan, M, 2014) |
| "Tau protein abnormally aggregates in tauopathies, a diverse group of neurologic diseases that includes Alzheimer's disease (AD)." | 1.56 | Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies. ( Bell, BM; Chakrabarty, P; Davies, P; Giasson, BI; Gorion, KM; Kim, JD; Manaois, AN; Prokop, S; Sorrentino, ZA; Xia, Y, 2020) |
| "A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau)." | 1.34 | The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. ( Ash, P; Bailey, RM; Burrows, F; Dickey, CA; Dickson, DW; Dunmore, J; Eckman, CB; Hutton, M; Kamal, A; Klosak, N; Lundgren, K; Nahman, NS; Patterson, C; Petrucelli, L; Shoraka, S; Zlatkovic, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobsen, AM | 1 |
| van de Merbel, NC | 1 |
| Ditlevsen, DK | 1 |
| Tvermosegaard, K | 1 |
| Schalk, F | 1 |
| Lambert, W | 1 |
| Bundgaard, C | 1 |
| Pedersen, JT | 1 |
| Rosenqvist, N | 1 |
| Xia, Y | 1 |
| Prokop, S | 1 |
| Gorion, KM | 1 |
| Kim, JD | 1 |
| Sorrentino, ZA | 1 |
| Bell, BM | 1 |
| Manaois, AN | 1 |
| Chakrabarty, P | 1 |
| Davies, P | 1 |
| Giasson, BI | 1 |
| Torres, AK | 1 |
| Jara, C | 1 |
| Olesen, MA | 1 |
| Tapia-Rojas, C | 1 |
| Antón-Fernández, A | 1 |
| Merchán-Rubira, J | 1 |
| Avila, J | 2 |
| Hernández, F | 1 |
| DeFelipe, J | 1 |
| Muñoz, A | 1 |
| Yarchoan, M | 1 |
| Toledo, JB | 1 |
| Lee, EB | 1 |
| Arvanitakis, Z | 1 |
| Kazi, H | 1 |
| Han, LY | 1 |
| Louneva, N | 1 |
| Lee, VM | 1 |
| Kim, SF | 1 |
| Trojanowski, JQ | 1 |
| Arnold, SE | 1 |
| Loeffler, DA | 1 |
| Smith, LM | 1 |
| Klaver, AC | 1 |
| Martić, S | 1 |
| Joo, Y | 1 |
| Schumacher, B | 1 |
| Landrieu, I | 2 |
| Bartel, M | 1 |
| Smet-Nocca, C | 1 |
| Jang, A | 1 |
| Choi, HS | 1 |
| Jeon, NL | 1 |
| Chang, KA | 1 |
| Kim, HS | 1 |
| Ottmann, C | 1 |
| Suh, YH | 1 |
| Xu, L | 1 |
| Ryu, J | 1 |
| Nguyen, JV | 1 |
| Arena, J | 1 |
| Rha, E | 1 |
| Vranis, P | 1 |
| Hitt, D | 1 |
| Marsh-Armstrong, N | 1 |
| Koliatsos, VE | 1 |
| Gasparini, L | 2 |
| Crowther, RA | 1 |
| Martin, KR | 1 |
| Berg, N | 1 |
| Coleman, M | 1 |
| Goedert, M | 3 |
| Spillantini, MG | 4 |
| Scattoni, ML | 1 |
| Alleva, E | 1 |
| Calamandrei, G | 1 |
| Hampton, DW | 1 |
| Webber, DJ | 1 |
| Bilican, B | 1 |
| Chandran, S | 1 |
| Iovino, M | 1 |
| Vuono, R | 1 |
| Combs, B | 1 |
| Voss, K | 1 |
| Gamblin, TC | 1 |
| de Calignon, A | 1 |
| Polydoro, M | 1 |
| Suárez-Calvet, M | 1 |
| William, C | 1 |
| Adamowicz, DH | 1 |
| Kopeikina, KJ | 1 |
| Pitstick, R | 1 |
| Sahara, N | 1 |
| Ashe, KH | 1 |
| Carlson, GA | 1 |
| Spires-Jones, TL | 1 |
| Hyman, BT | 1 |
| Ando, K | 1 |
| Dourlen, P | 1 |
| Sambo, AV | 1 |
| Bretteville, A | 1 |
| Bélarbi, K | 1 |
| Vingtdeux, V | 1 |
| Eddarkaoui, S | 1 |
| Drobecq, H | 1 |
| Ghestem, A | 1 |
| Bégard, S | 1 |
| Demey-Thomas, E | 1 |
| Melnyk, P | 1 |
| Smet, C | 1 |
| Lippens, G | 1 |
| Maurage, CA | 1 |
| Caillet-Boudin, ML | 1 |
| Verdier, Y | 1 |
| Vinh, J | 1 |
| Galas, MC | 1 |
| Blum, D | 1 |
| Hamdane, M | 1 |
| Sergeant, N | 1 |
| Buée, L | 1 |
| Pérez, M | 1 |
| Ribe, E | 1 |
| Rubio, A | 1 |
| Lim, F | 1 |
| Morán, MA | 1 |
| Ramos, PG | 1 |
| Ferrer, I | 1 |
| Isla, MT | 1 |
| Dickey, CA | 1 |
| Kamal, A | 1 |
| Lundgren, K | 1 |
| Klosak, N | 1 |
| Bailey, RM | 1 |
| Dunmore, J | 1 |
| Ash, P | 1 |
| Shoraka, S | 1 |
| Zlatkovic, J | 1 |
| Eckman, CB | 1 |
| Patterson, C | 1 |
| Dickson, DW | 1 |
| Nahman, NS | 1 |
| Hutton, M | 1 |
| Burrows, F | 1 |
| Petrucelli, L | 1 |
| Chun, W | 1 |
| Waldo, GS | 1 |
| Johnson, GV | 1 |
18 other studies available for serine and Tauopathies
| Article | Year |
|---|---|
A Quantitative LC-MS/MS Method for Distinguishing the Tau Protein Forms Phosphorylated and Nonphosphorylated at Serine-396.
Topics: Alzheimer Disease; Animals; Biomarkers; Chromatography, Liquid; Humans; Mice; Phosphorylation; Serin | 2023 |
Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Disease Models, Animal; HEK293 Cells; Humans; Mice, Inb | 2020 |
Pathologically phosphorylated tau at S396/404 (PHF-1) is accumulated inside of hippocampal synaptic mitochondria of aged Wild-type mice.
Topics: Aging; Animals; Cognitive Dysfunction; Hippocampus; Memory Disorders; Mice; Mice, Inbred C57BL; Mito | 2021 |
Phospho-Tau Accumulation and Structural Alterations of the Golgi Apparatus of Cortical Pyramidal Neurons in the P301S Tauopathy Mouse Model.
Topics: Animals; Carrier Proteins; Cerebral Cortex; Disease Models, Animal; Golgi Apparatus; Humans; Intrace | 2017 |
Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies.
Topics: Age Factors; Aged; Aged, 80 and over; alpha-Synuclein; Alzheimer Disease; Analysis of Variance; Anim | 2014 |
Effects of antibodies to phosphorylated and non-phosphorylated tau on in vitro tau phosphorylation at Serine-199: Preliminary report.
Topics: Animals; Antibodies, Monoclonal; Blotting, Western; In Vitro Techniques; Mice, Transgenic; Phosphory | 2015 |
Involvement of 14-3-3 in tubulin instability and impaired axon development is mediated by Tau.
Topics: 14-3-3 Proteins; Axons; Binding Sites; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cells | 2015 |
Evidence for accelerated tauopathy in the retina of transgenic P301S tau mice exposed to repetitive mild traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; Cell Count; Cerebral Cortex; Disease Models, Animal; | 2015 |
Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability.
Topics: Analysis of Variance; Animals; Axons; Bacterial Proteins; Disease Models, Animal; Humans; Inclusion | 2011 |
Early behavioural markers of disease in P301S tau transgenic mice.
Topics: Age Factors; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain; Cues; Disease Mode | 2010 |
Cell-mediated neuroprotection in a mouse model of human tauopathy.
Topics: Age Factors; Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Cell Trans | 2010 |
Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Cell Differentiation; Disease Mode | 2011 |
Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.
Topics: Amino Acid Substitution; Arachidonic Acid; Aspartic Acid; Biopolymers; Glutamic Acid; Glycogen Synth | 2011 |
Propagation of tau pathology in a model of early Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Animals; Disease Models, Animal; Disease Progression; Entorhinal Cor | 2012 |
Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Biomarkers; Brain; Cell Lin | 2013 |
Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Chromosomes, Human, Pair 17; | 2005 |
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Blood-Brain Barrier; Disease Models, Animal; DN | 2007 |
Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage.
Topics: Binding Sites; Biological Assay; Brain; Caspase 3; Cell Line; Enzyme Activation; Fluorescence; Glyco | 2007 |